LOGIN  |  REGISTER
Viking Therapeutics
Chimerix

Molina Healthcare Announces Third Quarter 2023 Earnings Release and Conference Call Dates

September 07, 2023 | Last Trade: US$332.38 3.12 -0.93

LONG BEACH, Calif. / Sep 07, 2023 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the third quarter ending September 30, 2023.

Molina Healthcare will issue its earnings release for the third quarter ending September 30, 2023, after the market closes on Wednesday, October 25, 2023, and will host a conference call and webcast to discuss the earnings release on Thursday, October 26, 2023, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 2183620. A telephonic replay of the conference call will be available through Thursday, November 2, 2023, by dialing (877) 344-7529 and entering the confirmation number, 3586044.

A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 126), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through its locally operated health plans, Molina Healthcare served approximately 5.2 million members as of June 30, 2023. For more information about Molina Healthcare, please visit molinahealthcare.com.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page